Testing more than one medication with a doctor is how many people determine which one fits their body best
With respect to the wider GLP-1 drug class, the UK SmPCs for semaglutide (available on the electronic Medicines Compendium, emc) and tirzepatide (Mounjaro SmPC, emc) document GI adverse effects including nausea, vomiting, diarrhoea, constipation, and dyspepsia as well-characterised class effects
Availability and FDA approval status This is perhaps the most practically important section of the entire comparison
Is the half-life different for brand-name Ozempic vs
Another study indicates that starting treatment with a lower dose and gradually increasing it helped reduce the incidence of gastrointestinal adverse events [64]
One important nuance: appetite suppression from retatrutide is not the same as having no appetite